Skip to content
Home/Companies/Biotech/Arvelle

Arvelle

Biotech·Switzerland·Exited 2021·Held 2yr
Entry
2019
Hold
2yr
Exit
2021

Who owns Arvelle?

Arvelle was owned by Andera Partners through BioDiscovery 5 (2017 vintage) from 2019 to 2021, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

Andera Partners
Investor
Andera Partners
BioDiscovery 5 · 2017 · VC

Key facts

HQSwitzerland
SectorBiotech
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2021

More from BioDiscovery 5

Other portfolio companies in the same fund.

Amolyt Pharma
Amolyt Pharma
Exited 2024
BiotechFrance· 2021
to
Evommune
Evommune
Exited 2025
BiotechFrance· 2021
to
Nyxoah
Nyxoah
Active
MedTechBelgium· 2020
AgoMab
AgoMab
Exited 2026
BiotechFrance· 2019
to
AM Pharma
AM Pharma
Active
BiotechNetherlands· 2019
Exciva
Active
BiotechUS· 2019

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Arvelle

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Arvelle?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Arvelle.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue